Alnylam Pharmaceuticals said this week that it has began a phase IIb trial of its siRNA-based respiratory syncytial virus drug ALN-RSV01 in adult lung transplant patients, on track with previous guidance.
GenomeWeb Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."
Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.
Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.
In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.
With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.